Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Genevieve Marie Boland, Ph.D., M.D.

Co-Author

This page shows the publications co-authored by Genevieve Boland and Keith Flaherty.
Connection Strength

3.251
  1. Tracking early response to immunotherapy. Nat Cancer. 2020 02; 1(2):160-162.
    View in: PubMed
    Score: 0.857
  2. Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy. Clin Cancer Res. 2021 11 01; 27(21):5993-6000.
    View in: PubMed
    Score: 0.238
  3. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nat Med. 2021 06; 27(6):985-992.
    View in: PubMed
    Score: 0.234
  4. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. J Immunother Cancer. 2021 02; 9(2).
    View in: PubMed
    Score: 0.230
  5. Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. Sci Adv. 2020 11; 6(46).
    View in: PubMed
    Score: 0.226
  6. Benefit and Toxicity to PD-1 Blockade Varies by Ethnicity in Patients with Advanced Melanoma: An International Multicenter Observational Study. Br J Dermatol. 2022 Mar 16.
    View in: PubMed
    Score: 0.062
  7. Combined tumor and immune signals from genomes or transcriptomes predict outcomes of checkpoint inhibition in melanoma. Cell Rep Med. 2022 Feb 15; 3(2):100500.
    View in: PubMed
    Score: 0.062
  8. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat Commun. 2021 10 15; 12(1):6023.
    View in: PubMed
    Score: 0.060
  9. Neural Crest-Like Stem Cell Transcriptome Analysis Identifies LPAR1 in Melanoma Progression and Therapy Resistance. Cancer Res. 2021 10 15; 81(20):5230-5241.
    View in: PubMed
    Score: 0.060
  10. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Sci Transl Med. 2021 02 17; 13(581).
    View in: PubMed
    Score: 0.058
  11. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma. Clin Cancer Res. 2020 11 15; 26(22):6039-6050.
    View in: PubMed
    Score: 0.056
  12. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nat Commun. 2020 08 07; 11(1):3946.
    View in: PubMed
    Score: 0.055
  13. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 Nov; 20(11):1555.
    View in: PubMed
    Score: 0.053
  14. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res. 2019 11 15; 25(22):6852-6867.
    View in: PubMed
    Score: 0.052
  15. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. Nat Immunol. 2019 09; 20(9):1231-1243.
    View in: PubMed
    Score: 0.052
  16. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunol Immunother. 2019 Jun; 68(6):897-905.
    View in: PubMed
    Score: 0.050
  17. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Mol Syst Biol. 2019 03 11; 15(3):e8323.
    View in: PubMed
    Score: 0.050
  18. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2019 Jan 10; 176(1-2):404.
    View in: PubMed
    Score: 0.050
  19. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2019 01; 565(7738):E4.
    View in: PubMed
    Score: 0.050
  20. ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma. Cancer Discov. 2019 03; 9(3):396-415.
    View in: PubMed
    Score: 0.050
  21. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.049
  22. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.049
  23. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 2018 11 01; 175(4):998-1013.e20.
    View in: PubMed
    Score: 0.049
  24. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018 10; 24(10):1545-1549.
    View in: PubMed
    Score: 0.048
  25. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. 2018 08 09; 174(4):843-855.e19.
    View in: PubMed
    Score: 0.048
  26. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. EMBO Mol Med. 2018 05; 10(5).
    View in: PubMed
    Score: 0.047
  27. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res. 2018 10 01; 24(19):4771-4784.
    View in: PubMed
    Score: 0.047
  28. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Rep. 2017 Dec 05; 21(10):2796-2812.
    View in: PubMed
    Score: 0.046
  29. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018 02; 8(2):196-215.
    View in: PubMed
    Score: 0.046
  30. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017 10 26; 8(1):1136.
    View in: PubMed
    Score: 0.046
  31. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. 2017 10 05; 550(7674):133-136.
    View in: PubMed
    Score: 0.046
  32. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Res. 2017 05 01; 77(9):2318-2327.
    View in: PubMed
    Score: 0.044
  33. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 2017 Apr 11; 8(15):25395-25417.
    View in: PubMed
    Score: 0.044
  34. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest. 2015 Apr; 125(4):1459-70.
    View in: PubMed
    Score: 0.038
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.